Welcome to our dedicated page for Davita news (Ticker: DVA), a resource for investors and traders seeking the latest updates and insights on Davita stock.
DaVita Inc. (NYSE: DVA) is a comprehensive kidney care provider whose news flow reflects its clinical, operational and financial activities in the kidney dialysis centers industry. Company press releases and updates highlight its focus on transforming care delivery for patients with kidney disease, its large global network of outpatient dialysis centers and its role in integrated kidney care and value-based care models.
News about DaVita often covers quarterly financial and operating results, where the company reports consolidated revenues, operating income, cash flow and key U.S. dialysis metrics such as treatment volumes, revenue per treatment and patient care costs per treatment. These releases may also discuss share repurchases, debt transactions, credit facility amendments and guidance ranges for adjusted operating income, adjusted diluted net income per share and free cash flow.
Investors and observers can also find updates on clinical research and innovation. DaVita publishes information about studies presented at events like the American Society of Nephrology’s Kidney Week, including research on GLP-1 receptor agonist use in end-stage kidney disease, home dialysis outcomes, transplant access and end-of-life care. Additional news may describe initiatives such as the MODEL and MEMOIRS evaluations of medium cut-off dialyzers and efforts to better understand middle-molecule clearance.
Other DaVita news items include leadership appointments, participation in investor conferences and statements on government programs such as the Kidney Care Choices (KCC) Model. These communications provide insight into the company’s strategy, governance, integrated kidney care footprint and engagement with value-based care initiatives. For ongoing context on DVA, readers can use this news feed to follow developments in DaVita’s kidney care operations, research programs and capital allocation decisions over time.
The American Diabetes Association (ADA) and DaVita announced the launch of a digital platform aimed at combating diabetes-related kidney complications on July 25, 2022. This initiative targets the one in seven U.S. adults affected by diabetes, which is the leading cause of chronic kidney disease (CKD). The platform offers resources including Kidney Smart classes, meal planning, and physician engagement tips to empower diabetes patients. Dr. Robert Gabbay of ADA emphasized the importance of understanding the diabetes-kidney connection to improve health outcomes.
DaVita Inc. (NYSE: DVA) announced its quarterly conference call to discuss second quarter results on August 1, 2022, at 5:00 p.m. ET. Results will be released after market close the same day. Investors can access the call via dial-in at 877-918-6630 or through a webcast at the DaVita IR website. As of March 31, 2022, DaVita served 200,800 patients across 2,809 outpatient dialysis centers in the U.S. and 346 centers in other countries, focusing on improving kidney care quality.
Rockwell Medical (RMTI) has successfully closed a $7.5 million second tranche investment from DaVita (DVA), bringing the total capital raised this quarter to $30 million. This funding will extend Rockwell's cash runway to advance its Ferric Pyrophosphate Citrate (FPC) development programs and improve their dialysis business. They are preparing for a Phase 2 clinical trial of FPC in home infusion patients, pending FDA clearance, which will require a microbial challenge study to ensure patient safety.
DaVita Inc. (NYSE: DVA) announced a special investor conference call scheduled for June 23, 2022, at 8:45 a.m. EDT. The call follows a U.S. Supreme Court ruling concerning the Medicare Secondary Payor Act. Investors can join the call via a designated phone number or listen to a webcast. DaVita is focused on enhancing kidney care, having served 200,800 patients at 2,809 outpatient dialysis centers in the U.S. as of March 31, 2022. The company aims to improve patient outcomes and accessibility in kidney health.
Medtronic and DaVita are launching a new independent company focused on kidney care technology to enhance treatment experiences and patient outcomes. This collaboration aims to leverage Medtronic's healthcare technology skills and DaVita's expertise in kidney care to develop innovative products, including home-based dialysis solutions. Each company will hold equal stakes in the new entity, which will be governed by an independent management team. The transaction is expected to close within a year, pending regulatory approvals.
Medtronic and DaVita have announced a partnership to create a new independent kidney care-focused medical device company, NewCo. This joint venture aims to enhance kidney treatment and patient outcomes by leveraging Medtronic's healthcare technology and DaVita's expertise in kidney care. NewCo will develop innovative therapies and products, especially for home-based dialysis treatments, serving over three million kidney failure patients globally. Each company will have equal ownership and contribute financially to support NewCo's initial operations.
Dosis has rolled out its Smart Anemia Manager (SAM) at DaVita clinics nationwide, enhancing personalized dosing for erythropoiesis-stimulating agents (ESAs) used in treating chronic anemia in end-stage renal disease patients. This integration, which began in 2019, has influenced over 30 million dialysis treatments. CEO Shivrat Chhabra emphasized the importance of precision medicine in value-based care, aiming to improve patient outcomes while lowering healthcare costs through tailored dosing recommendations.
Summary not available.
DaVita Inc. (NYSE: DVA) announced that its CFO, Joel Ackerman, will participate in a fireside chat with investors at the Bank of America Securities 2022 Healthcare Conference on May 10, 2022, at 11 a.m. EDT. Stakeholders can access the live webcast by registering on the Bank of America Securities page.
DaVita is a leading kidney care provider, serving 203,000 patients across 2,815 U.S. outpatient dialysis centers and 339 centers globally.
DaVita reported Q1 2022 financial results, highlighting a net income of $162 million, down from $237 million year-over-year. Diluted EPS was $1.61, a 10.1% decrease from the previous quarter, influenced by COVID-19 impacts and wage increases. Consolidated revenues reached $2.818 billion. Operating income fell to $338 million with a 12.0% margin. There was a decline in U.S. dialysis treatments by 2.2% from Q4 2021. DaVita continues to provide care to over 241,800 patients across 3,155 centers globally, despite opening nine new centers in Q1. The company also repurchased 2.1 million shares during this period.